Annual report pursuant to Section 13 and 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)

v3.24.2.u1
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Common Stock, dividends, per share, declared (in dollars per share) $ 0.32 $ 0.32 $ 0.32
Stock Repurchased During Period, Shares (in shares) 1,397,471 222,000 1,576,952
Average price per share of shares repurchased $ 57.28 $ 88.12 $ 102.06
Net settlement stock options exercises and restricted stock units vesting $ 21,872 $ 28,893 $ 23,461
Interest expense 15,736 11,215 11,309
Total other income (expense), net (20,997) 39,715 4,796
Income Tax Expense (Benefit), Total 17,584 53,217 38,287
Net Deferred Tax Liability 165,186 184,005  
Deferred Income Tax Expense (Benefit), Total (40,161) (29,799) 7,063
Eminence Biotechnology      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest   33 70
Accumulated Other Comprehensive Income      
Net Deferred Tax Liability $ 2,500 $ 4,000 $ 2,500